
The randomized, double-blind trial evaluates whether dexamethasone eye drops (1 mg/ml) can reduce progression to Type 1 retinopathy of prematurity (ROP) in infants <30 weeks gestation. One hundred infants in Sweden will be randomized to dexamethasone or placebo until ROP resolves or requires treatment. Primary outcome is Type 1 ROP incidence. Safety, side effects, and long-term ophthalmologic outcomes will also be assessed at 2 and 5.5 years.
Like
Save
Share